l-Asparagine Synthetase in Serum as a Marker for Neoplasia

Summary

l-Asparagine synthetase appears in serum approximately 7 days after the s.c. implantation of 1 × 10⁵ cells of Leukemia 5178Y/AR (resistant to l-asparaginase) and increases in activity as the neoplasm grows and metastasizes. The principal source of the enzyme is the primary tumor. After intracranial inoculation of tumor, the rate of leakage of the enzyme is more pronounced than when the subcutaneous, intramuscular, or intraperitoneal routes are used. 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037), a nitrosourea effective in the palliation of L5178Y/AR. temporarily halts the influx of enzyme into the blood stream, as does surgical excision of the s.c. tumor nodules. Treatment of mice with l-asparaginase within 24 hr of inoculation of the tumor markedly augments both tumor growth and the rate of penetration of l-asparagine synthetase into the circulation. Several other l-asparaginase-resistant tumors also were found to spill l-asparagine synthetase into the serum, but the correlation between this phenomenon and the specific activity of the enzyme in homogenates of the tumor was imperfect.